|Enhancer of zeste 2 polycomb repressive complex 2 subunit|
Ribbon diagram of 233-residue fragment of EZH2 (residues 520-753) crystallized with zinc ion based on ]
|Symbols||; ENX-1; ENX1; EZH1; EZH2b; KMT6; KMT6A; WVS; WVS2|
|External IDs||IUPHAR: GeneCards:|
|RNA expression pattern|
Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme (EC 188.8.131.52) encoded by EZH2 gene, that participates in DNA methylation and, ultimately, transcriptional repression. EZH2 catalyzes the addition of methyl groups to histone H3 at lysine 27, by using the cofactor S-adenosyl-L-methionine. Methylation activity of EZH2 facilitates heterochromatin formation thereby silences gene function. Remodeling of chromosomal heterochromatin by EZH2 is also required during cell mitosis.
EZH2 is the functional enzymatic component of the polycomb repressive complex 2 (PRC2), which is responsible for healthy embryonic development through the epigenetic maintenance of genes responsible for regulating development and differentiation. EZH2 is responsible for the methylation activity of PRC2, and the complex also contains proteins required for optimal function (EED, SUZ12, JARID2, AEBP2, RbAp46/48, and PCL).
EZH2 inhibits genes responsible for suppressing tumor development, and blocking EZH2 activity may slow tumor growth. EZH2 has been targeted for inhibition because it is upregulated in multiple cancers including, but not limited to, breast, prostate, melanoma, and bladder cancer. Mutations in the EZH2 gene are also associated with Weaver syndrome, a rare congenital disorder, and EZH2 is involved in causing neurodegenerative symptoms in the nervous system disorder, ataxia telangiectasia.
- 1 Function
- 2 Enzymatic activity
- 3 Clinical significance
- 4 Taxonomic distribution
- 5 References
- 6 Further reading
|PDB structures||RCSB PDB PDBe PDBsum|
EZH2 is the catalytic subunit of the Polycomb repressive complex 2 (PRC2). EZH2's catalytic activity relies on its formation of a complex with at least two other PRC2 components, SUZ12 and EED. As a histone methyltransferase (HMTase), EZH2's primary function is to methylate Lys-27 on histone 3 (H3K27me) by transferring a methyl group from the cofactor S-adenosyl-L-methionine (SAM), although recent studies have indicated that it is also capable of methylating non-histone proteins. EZH2 is capable of mono-, di-, and tri-methylation of H3K27 and has been associated with a variety of biological functions, including transcriptional repression and activation, hematopoiesis, development, and cell differentiation.
EZH2, as a part of PRC2, catalyzes trimethylation of H3K27 (H3K27me3), which is a histone modification that has been characterized as part of the histone code. The histone code is the theory that chemical modifications, such as methylation, acetylation, and ubiquitination, of histone proteins play distinctive roles in epigenetic regulation of gene transcription. EZH2-mediated catalysis of H3K27me3 is associated with long term transcription repression.
EZH2, as well as other Polycomb group proteins, are involved in establishing and maintaining gene repression through cell division. This transcriptionally repressive state is thought to be due to PRC2/EZH2-EED-mediated H3K27 methylation and subsequent recruitment of PRC1 which facilitates condensation of chromatin and formation of heterochromatin. Heterochromatin is tightly packed chromatin which limits the accessibility of transcription machinery to the underlying DNA, thereby suppressing transcription.
During cell division, heterochromatin formation is required for proper chromosome segregation. PRC2/EED-EZH2 complex may also be involved in the recruitment of DNA methyltransferases (DNMTs), which results in increased DNA methylation, another epigenetic layer of transcription repression. Specific genes that have been identified as targets of EZH2-mediated transcriptional repression include HOXA9, HOXC8, MYT1, CDKN2A and retinoic acid target genes.
In cancer, EZH2 may play a role in activation of transcription, independently of PRC2. In breast cancer cells, EZH2 has been demonstrated to activate NF-κB target genes, which are involved in responses to stimuli. The functional role of this activity and its mechanism are still unknown.
Development and cell differentiation
EZH2 plays an essential role in development. In particular, it helps control transcriptional repression of genes that regulate cell differentiation. In embryonic stem cells, EZH2-mediated trimethylation of H3K27me3 in regions containing developmental genes appears to be important for maintenance of normal cell differentiation. H3K27me3 is also important in driving X-inactivation, the silencing of one X-chromosome in females during development. During X-inactivation, it is thought that EZH2 is involved in initiating heterochromatin formation by trimethylating H3K27 and that other histone methyltransferases and histone marks may be involved in maintaining the silenced state.
Further, EZH2 has been identified as an essential protein involved in development and differentiation of B-cells and T-cells. H3K27me3 is involved in suppressing genes that promote differentiation, thus maintaining an undifferentiated state of B- and T-cells and playing an important role in regulating hematopoiesis.
Regulation of EZH2 activity
The activity of EZH2 is regulated by the post-translational phosphorylation of threonine and serine residues on EZH2. Specifically, phosphorylation of T350 has been linked to an increase in EZH2 activity while phosphorylation of T492 and S21 have been linked to a decrease in EZH2 activity. Phosphorylation of T492 has been suggested to disrupt contacts between human EZH2 and its binding partners in the PRC2 complex, thus hindering its catalytic activity.
In addition to phosphorylation, it has also been shown that PRC2/EZH2-EED activity is antagonized by transcription-activating histone marks, such as acetylation of H3K27 (H3K27ac) and methylation of H3K36 (H3K36me).
EZH2 function is highly dependent upon its recruitment by the PRC2 complex. In particular, WD40-repeat protein embyronic ectoderm development (EED) and zinc finger protein suppressor of zeste 12 (SUZ12) are needed to stabilize the interaction of EZH2 with its histone substrate Recently, two isoforms of EZH2 generated from alternative splicing have been identified in humans: EZH2α and EZH2β. Both isoforms contain elements that have been identified as important for EZH2 function including the nuclear localization signal, the EED and SUZ12 binding sites as well as the conserved SET domain. Most studies have thus far focused on the longer isoform EZH2α, but EZH2β, which lacks exons 4 and 8, has been shown to be active. Furthermore, PRC2/EZH2β complexes act on distinct genes from that of its PRC2/EZH2α counterpart suggesting that each isoform may act to regulate a specific subset of genes. Additional evidence suggests that EZH2 may also be capable of lysine methylation independent of association with PRC2, when EZH2 is highly upregulated.
Methylation is the addition of a -CH3, or methyl group, to another molecule. In biology, methylation is typically catalyzed by enzymes, and methyl groups are commonly added to either proteins or nucleic acids. In EZH2-catalyzed methylation, the amino acid lysine in the histone h3 is methylated. This amino acid residue can be methylated up to three times on its terminal ammonium group. These methylated lysines are important in the control of mammalian gene expression and have a functional role in heterochromatin formation, X-chromosome inactivation and transcriptional regulation. In mammalian chromosomes, histone lysine methylation can either activate or repress genes depending the site of methylation. Recent work has shown that at least part of the silencing function of the EZH2 complex is the methylation of histone H3 on lysine 27. Methylation, and other modifications, take place on the histones. Methyl modifications can affect the binding of proteins to these histones and either activate or inhibit transcription.
Mechanism of catalysis
EZH2 is a member of the SET domain family of lysine methyltransferases which function to add methyl groups to lysine side chains of substrate proteins. SET methyltransferases depend on a SAM cofactor to act as a methyl donor for their catalytic activity. SET domain proteins differ from other SAM-dependent methyltransferases in that they bind their substrate and SAM cofactor on opposite sides of the active site of the enzyme. This orientation of substrate and cofactor allows SAM to dissociate without disrupting substrate binding and can lead to multiple rounds of lysine methylation without substrate dissociation.
Although neither a substrate-bound or SAM-bound crystal structure for EZH2 has been determined, STAMP structure alignment with the human SET7/9 methyltransferase shows conserved tyrosine residues in almost identical positions within the putative active site of EZH2.
It had been previously suggested that tyrosine 726 in the EZH2 active site was acting as a general base to de-protonate the substrate lysine but kinetic isotope effects have indicated that active site residues are not directly involved in the chemistry of the methyltransferase reaction. Instead these experiments support a mechanism in which the residues lower the pKa of the substrate lysine residue while simultaneously providing a channel for water to access the lysine side chain within the interior of the active site. Bulk solvent water can then easily deprotonate the lysine side chain, activating it for nucleophilic attack of the SAM cofactor in an SN2-like reaction resulting in transfer of the methyl group from SAM to the lysine side chain.
EZH2 primarily catalyzes mono- and di-methylation of H3K27 but a clinically relevant mutation of residue tyrosine 641 to phenylalanine (Y641F) results in higher H3K27 tri-methylation activity. It is proposed that the removal of the hydroxyl group on Y641 abrogates steric hinderance and allows for accommodation of a third methyl group on the substrate lysine. This EZH2 Y641F mutant is associated with many cancer phenotypes and implies that Y641 may be involved in regulating the number of methyl groups added to a single lysine residue.
EZH2 is an attractive target for anti-cancer therapy because it helps cancerous cells divide and proliferate. It is found in larger amounts than in healthy cells in a wide range of cancers including breast, prostate, bladder, uterine, and renal cancers, as well as melanoma and lymphoma. EZH2 is a gene suppressor, so when it becomes overexpressed, many tumor suppressor genes that are normally turned on, are turned off. Inhibition of EZH2 function shrinks malignant tumors in some reported cases because those tumor suppressor genes are not silenced by EZH2. EZH2 typically is not expressed in healthy adults; it is only found in actively dividing cells, like those active during fetal development. Because of this characteristic, overexpression of EZH2 can be used as a diagnostic marker of cancer and some neurodegenerative disorders. However, there are cases where it is difficult to tell whether overexpression of EZH2 is the cause of a disease, or simply a consequence. If it is only a consequence, targeting EZH2 for inhibition may not cure the disease. One example of a cancer pathway in which EZH2 plays a role is the pRB-E2F pathway. It is downstream from the pRB-E2F pathway, and signals from this pathway lead to EZH2 overexpression. Another important characteristic of EZH2 is that when EZH2 is overexpressed, it can activate genes without forming PRC2. This is an issue because it means the methylation activity of the enzyme is not mediated by complex formation. In breast cancer cells, EZH2 activates genes that promote cell proliferation and survival. It can also activate regulatory genes like c-myc and cyclin D1 by interacting with Wnt signaling factors. Importantly, the mutation of tyrosine 641 to phenylalanine in the active SET domain of EZH2 results in preference for H3K27 tri-methylation and has been linked to lymphoma.
Developing an inhibitor of EZH2 and preventing unwanted histone methylation of tumor suppressor genes is a viable area of cancer research. EZH2 inhibitor development has focused on targeting the SET domain active site of the protein. Several inhibitors of EZH2 have been developed as of 2015, including 3-deazaneplanocin A (DZNep), EPZ005687, EI1, GSK126, and UNC1999. DZNep has potential antiviral and anti-cancer properties because it lowers EZH2 levels and induces apoptosis in breast and colon cancer cells. DZNep inhibits the demethylation of S-adenosyl-L-methionine, the cofactor of EZH2, to form S-adenosyl-L-homocysteine, therefore blocking the transfer of the methyl group to a histone. However, DZNep is not specific to EZH2 and also inhibits other DNA methyltransferases.
In 2012, a company called Epizyme revealed EPZ005687, an S-adenosylmethionine (SAM) inhibitor that is more selective than DZNep; it has a 50-fold increase in selectivity for EZH2 compared to EZH1. The drug blocks EZH2 activity by binding to the SET domain active site of the enzyme. EPZ005687 can also inhibit the Y641 and A677 mutants of EZH2, which may be applicable for treating non-Hodgkin's lymphoma. In 2013, Epizyme began Phase I clinical trials with another EZH2 inhibitor, EPZ-6438, for patients with B-cell lymphoma.
Sinefungin is another SAM-competitive inhibitor similar to DZNep, however, like DZNep, it is not specific to EZH2. It works by binding in the cofactor binding pocket of DNA methyltransferases to block methyl transfer. EI1 is another inhibitor, developed by Novartis, that showed EZH2 inhibitory activity in lymphoma tumor cells, including cells with the Y641 mutation. The mechanism of this inhibitor also involves competing with the SAM cofactor for binding to EZH2. GSK126 is a potent, SAM-competitive EZH2 inhibitor developed by GlaxoSmithKline, that has 150-fold selectivity over EZH1 and a Ki of 0.5-3 nM. UNC1999 was developed as an analogue of GSK126, and was the first orally bioavailable EZH2 inhibitor to show activity. However, it is less selective than its counterpart GSK126, and it binds to EZH1 as well, increasing the potential for off-target effects.
Combination therapies are being studied as possible treatments when primary treatments begin to fail. Etoposide, a topoisomerase inhibitor, when combined with an EZH2 inhibitor, becomes more effective for non-small cell lung cancers with BRG1 and EGFR mutations. However, EZH2 and lysine methylation can have tumor suppressing activity, for example in myelodysplastic syndrome, indicating that EZH2 inhibition may not be beneficial in all cases.
Mutations in the EZH2 gene have been linked with Weaver syndrome, a rare disorder characterized by advanced bone age, macrocephaly, and hypertelorism. The histidine residue in the active site of the wild-type EZH2 was mutated to tyrosine in patients with diagnosed with Weaver syndrome. The mutation likely interferes with cofactor binding and causes disruption of the natural function of the protein.
Enhancer of zeste (E(z)) was originally identified in Drosophila melanogaster, and its mammalian homologs were subsequently identified and named EZH1 (enhancer of zeste homolog 1) and EZH2 (enhancer of zeste homolog 2). EZH2 is highly conserved through evolution. It and its homologs play essential roles in development, cell differentiation, and cell division in plants, insects, fish, and mammals. The following taxonomic tree is a depiction of EZH2's distribution throughout a wide variety of species.
- Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. (2006). "The Polycomb group protein EZH2 directly controls DNA methylation". Nature 439 (7078): 871–4. doi:10.1038/nature04431. PMID 16357870.
- Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. (2002). "Role of histone H3 lysine 27 methylation in Polycomb-group silencing". Science 298 (5595): 1039–43. doi:10.1126/science.1076997. PMID 12351676.
- Morey L, Helin K (2010). "Polycomb group protein-mediated repression of transcription". Trends Biochem. Sci. 35 (6): 323–32. doi:10.1016/j.tibs.2010.02.009. PMID 20346678.
- Margueron R, Reinberg D (2011). "The Polycomb complex PRC2 and its mark in life". Nature 469 (7330): 343–9. doi:10.1038/nature09784. PMC 3760771. PMID 21248841.
- Yoo KH, Hennighausen L (2012). "EZH2 methyltransferase and H3K27 methylation in breast cancer". Int. J. Biol. Sci. 8 (1): 59–65. doi:10.7150/ijbs.8.59. PMC 3226033. PMID 22211105.
- Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. (2002). "The polycomb group protein EZH2 is involved in progression of prostate cancer". Nature 419 (6907): 624–9. doi:10.1038/nature01075. PMID 12374981. Lay summary – Scientific American.
- Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P et al. (2015). "The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors". Nat Commun 6: 6051. doi:10.1038/ncomms7051. PMID 25609585. Lay summary – MedicalResearch.com.
- Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caşkurlu T, Cakir OO, Ergenekon E (2005). "Increased expression of EZH2, a polycomb group protein, in bladder carcinoma". Urol. Int. 75 (3): 252–7. doi:10.1159/000087804. PMID 16215315.
- Gibson WT, Hood RL, Zhan SH, Bulman DE, Fejes AP, Moore R et al. (2012). "Mutations in EZH2 cause Weaver syndrome". Am. J. Hum. Genet. 90 (1): 110–8. doi:10.1016/j.ajhg.2011.11.018. PMC 3257956. PMID 22177091.
- Li J, Hart RP, Mallimo EM, Swerdel MR, Kusnecov AW, Herrup K (2013). "EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia". Nat. Neurosci. 16 (12): 1745–53. doi:10.1038/nn.3564. PMC 3965909. PMID 24162653.
- Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE (2014). "EZH2: biology, disease, and structure-based drug discovery". Acta Pharmacol. Sin. 35 (2): 161–74. doi:10.1038/aps.2013.161. PMC 3914023. PMID 24362326.
- Lund K, Adams PD, Copland M (2014). "EZH2 in normal and malignant hematopoiesis". Leukemia 28 (1): 44–9. doi:10.1038/leu.2013.288. PMID 24097338.
- "RefSeq". RefSeq Gene EZH2. Retrieved February 1, 2015.
- Ding X, Wang X, Sontag S, Qin J, Wanek P, Lin Q et al. (2014). "The polycomb protein Ezh2 impacts on induced pluripotent stem cell generation". Stem Cells Dev. 23 (9): 931–40. doi:10.1089/scd.2013.0267. PMC 3996971. PMID 24325319.
- O'Meara MM, Simon JA (2012). "Inner workings and regulatory inputs that control Polycomb repressive complex 2". Chromosoma 121 (3). doi:10.1007/s00412-012-0361-1. PMID 22349693.
- "Histone H3K27". EpiGenie.
- Grewal SI, Jia S (2007). "Heterochromatin revisited". Nat. Rev. Genet. 8 (1): 35–46. doi:10.1038/nrg2008. PMID 17173056.
- Stewart MD, Li J, Wong J (2005). "Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment". Mol. Cell. Biol. 25 (7): 2525–2538. doi:10.1128/MCB.25.7.2525-2538.2005. PMID 15767660.
- Jeanteur, Philippe (2008). Epigenetics and Chromatin. Springer.
- Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA et al. (2010). "Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA". Genes Dev. 24 (23): 2615–20. doi:10.1101/gad.1983810. PMC 2994035. PMID 21123648.
- Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, Zlobin A et al. (2009). "CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing". Development 136 (18): 3131–41. doi:10.1242/dev.037127. PMC 2730368. PMID 19700617.
- Cao R, Zhang Y (2004). "SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex". Mol. Cell 15 (1): 57–67. doi:10.1016/j.molcel.2004.06.020. PMID 15225548.
- Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K (1998). "Point mutations in the WD40 domain of Eed block its interaction with Ezh2". Mol. Cell. Biol. 18 (10): 5634–42. PMC 109149. PMID 9742080.
- Grzenda A, Lomberk G, Svingen P, Mathison A, Calvo E, Iovanna J et al. (February 28, 2013). "Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression". Epigenetics & Chromatin 6 (1). doi:10.1186/1756-8935-6-3.
- Martin C, Zhang Y (2005). "The diverse functions of histone lysine methylation". Nat. Rev. Mol. Cell Biol. 6 (11): 838–849. doi:10.1038/nrm1761. PMID 16261189.
- Brien GL, Gambero G, O'Connell DJ, Jerman E, Turner SA, Egan CM et al. (2012). "Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation". Nat. Struct. Mol. Biol. 19 (12): 1273–1281. doi:10.1038/nsmb.2449. PMID 23160351.
- Dillon SC, Zhang X, Trievel RC, Cheng X (2005). "The SET-domain protein superfamily: protein lysine methyltransferases" (PDF). Genome Biol. 6 (8). doi:10.1186/gb-2005-6-8-227. Retrieved February 1, 2015.
- Kipp DR, Quinn CM, Fortin PD (2013). "Enzyme-dependent lysine deprotonation in EZH2 catalysis". Biochemistry 52 (39): 6866–78. doi:10.1021/bi400805w. PMID 24000826.
- "'Window of Vulnerability'". Harvard Medical School.
- Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ et al. (2013). "An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1". ACS Chem. Biol. 8 (6): 1324–34. doi:10.1021/cb400133j. PMC 3773059. PMID 23614352.
- Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003). "EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer". EMBO J. 22 (20): 5323–35. doi:10.1093/emboj/cdg542. PMC 213796. PMID 14532106.
- Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H et al. (2007). "Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells". Mol. Cell. Biol. 27 (14): 5105–19. doi:10.1128/MCB.00162-07. PMC 1951944. PMID 17502350.
- Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. (2010). "Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin". Nat. Genet. 42 (2): 181–5. doi:10.1038/ng.518. PMC 2850970. PMID 20081860.
- Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. (2007). "Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells". Genes Dev. 21 (9): 1050–63. doi:10.1101/gad.1524107. PMC 1855231. PMID 17437993.
- Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR et al. (2012). "A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells". Nat. Chem. Biol. 8 (11): 890–6. doi:10.1038/nchembio.1084. PMID 23023262.
- Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R et al. (2012). "Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation". Proc. Natl. Acad. Sci. U.S.A. 109 (52): 21360–5. doi:10.1073/pnas.1210371110. PMC 3535655. PMID 23236167.
- McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. (2012). "EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations". Nature 492 (7427): 108–12. doi:10.1038/nature11606. PMID 23051747.
- Couture JF, Hauk G, Thompson MJ, Blackburn GM, Trievel RC (2006). "Catalytic roles for carbon-oxygen hydrogen bonding in SET domain lysine methyltransferases". J. Biol. Chem. 281 (28): 19280–7. doi:10.1074/jbc.M602257200. PMID 16682405.
- Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium. (2014, October 1).
- Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER et al. (2010). "Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes". Nat. Genet. 42 (8): 665–7. doi:10.1038/ng.620. PMID 20601954.
- "Ensembl". Gene Tree EZH2. Retrieved February 19, 2015.
- Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A et al. (1997). "Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres". EMBO J. 16 (11): 3219–32. doi:10.1093/emboj/16.11.3219. PMC 1169939. PMID 9214638.
- "NCBI UniGene". Enhancer of zeste homolog 2 (Drosophila) (EZH2). Retrieved February 1, 2015.
- "GeneCards". Enhancer Of Zeste Homolog 2 (Drosophila). Retrieved February 1, 2015.
- "Ensembl". Gene Tree EZH2. Retrieved February 1, 2015.
- Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S et al. (2014). "Ensembl 2014". Nucleic Acids Res. 42 (Database issue): D749–55. doi:10.1093/nar/gkt1196. PMC 3964975. PMID 24316576.
- Zeidler M, Kleer CG (Sep 2006). "The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer". Journal of Molecular Histology 37 (5-7): 219–23. doi:10.1007/s10735-006-9042-9. PMID 16855786. Check date values in:
|year= / |date= mismatch(help)
- De Haan G, Gerrits A (Jun 2007). "Epigenetic control of hematopoietic stem cell aging the case of Ezh2". Annals of the New York Academy of Sciences 1106 (1): 233–9. doi:10.1196/annals.1392.008. PMID 17332078.
- Hobert O, Jallal B, Ullrich A (Jun 1996). "Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression". Molecular and Cellular Biology 16 (6): 3066–73. PMC 231301. PMID 8649418.
- Bonaldo MF, Lennon G, Soares MB (Sep 1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Research 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548. Check date values in:
|year= / |date= mismatch(help)
- Abel KJ, Brody LC, Valdes JM, Erdos MR, McKinley DR, Castilla LH et al. (Oct 1996). "Characterization of EZH1, a human homolog of Drosophila Enhancer of zeste near BRCA1". Genomics 37 (2): 161–71. doi:10.1006/geno.1996.0537. PMID 8921387. Check date values in:
|year= / |date= mismatch(help)
- Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A et al. (Jun 1997). "Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres". The EMBO Journal 16 (11): 3219–32. doi:10.1093/emboj/16.11.3219. PMC 1169939. PMID 9214638.
- Cardoso C, Timsit S, Villard L, Khrestchatisky M, Fontès M, Colleaux L (Apr 1998). "Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein". Human Molecular Genetics 7 (4): 679–84. doi:10.1093/hmg/7.4.679. PMID 9499421.
- van Lohuizen M, Tijms M, Voncken JW, Schumacher A, Magnuson T, Wientjens E (Jun 1998). "Interaction of mouse polycomb-group (Pc-G) proteins Enx1 and Enx2 with Eed: indication for separate Pc-G complexes". Molecular and Cellular Biology 18 (6): 3572–9. PMC 108938. PMID 9584197.
- Sewalt RG, van der Vlag J, Gunster MJ, Hamer KM, den Blaauwen JL, Satijn DP et al. (Jun 1998). "Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes". Molecular and Cellular Biology 18 (6): 3586–95. PMC 108940. PMID 9584199.
- Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K (Oct 1998). "Point mutations in the WD40 domain of Eed block its interaction with Ezh2". Molecular and Cellular Biology 18 (10): 5634–42. PMC 109149. PMID 9742080.
- van der Vlag J, Otte AP (Dec 1999). "Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation". Nature Genetics 23 (4): 474–8. doi:10.1038/70602. PMID 10581039.
- Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, Colleaux L (Mar 2000). "The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders". European Journal of Human Genetics : EJHG 8 (3): 174–80. doi:10.1038/sj.ejhg.5200439. PMID 10780782.
- Raaphorst FM, Otte AP, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM et al. (May 2001). "Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation". Journal of Immunology (Baltimore, Md. : 1950) 166 (10): 5925–34. doi:10.4049/jimmunol.166.10.5925. PMID 11342607.
- O'Connell S, Wang L, Robert S, Jones CA, Saint R, Jones RS (Nov 2001). "Polycomblike PHD fingers mediate conserved interaction with enhancer of zeste protein". The Journal of Biological Chemistry 276 (46): 43065–73. doi:10.1074/jbc.M104294200. PMID 11571280.
- Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. (Oct 2002). "The polycomb group protein EZH2 is involved in progression of prostate cancer". Nature 419 (6907): 624–9. doi:10.1038/nature01075. PMID 12374981.
- Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. (Sep 2003). "EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells". Proceedings of the National Academy of Sciences of the United States of America 100 (20): 11606–11. doi:10.1073/pnas.1933744100. PMC 208805. PMID 14500907.